Human papillomavirus (HPV) is a common infectious disease that affects nearly 14 million Americans each year and can lead to cervical, oropharyngeal, and other cancers. Every year, more than 30,000 people are affected by an HPV-related cancer. The Centers for Disease Control and Prevention recommends routine HPV vaccination for adolescent girls and boys beginning at age 11; however, nationally, 38 percent of girls and 50 percent of boys have not received at least one dose of the vaccine and even fewer have completed the recommended vaccine series.
With the support of PCORI Pipeline to Proposal funding, we developed the Infectious Diseases Community Coalition Board, a group of patients, parents, researchers, healthcare providers, school nurses, and community leaders, with the mission to develop and test interventions to increase HPV vaccination rates in the greater Kansas City metropolitan area. During Tier I, we built and formalized our partnership, and worked collaboratively to develop a list of comparative effectiveness research (CER) questions to increase HPV vaccination uptake. In Tier II, we built on this collaborative process and finalized our CER question, engaged other stakeholder organizations, and submitted external funding applications to support pilot data collection.
During Tier III, we will build on our current work to finalize our research strategy and engage board members and local, state, and regional stakeholders to develop, revise, and submit a Letter of Intent and full proposal for a broad PCORI funding opportunity.